Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Consumer Motivation for Disease Prevention

5 de abril de 2019 actualizado por: Yeung Wing Man, Chinese University of Hong Kong
The purpose of this study is to examine (1) how the causal structure of a disease influences people's disease prevention decisions; and (2) how the causal structure of a disease interacts with people's regret anticipation in determining their disease prevention decisions.

Descripción general del estudio

Descripción detallada

People sometimes have to deliberate on whether or not to remove a risk factor that may potentially cause a disease in the future. When a controllable risk factor (say, X) is the only factor that causes a disease, the decision to remove it may simply depend on the probabilistic relationship between X and an outcome, as well as the cost of removing X. However, little is known when other factors that are out of the decision-maker's control are also present. The main question being asked here is how does the presence of such uncontrollable factors change people's decision to remove X.

Specifically, the investigators consider two cases: a disease caused by a single controllable risk factor (say X) and a disease caused by two risk factors -- a controllable factor (X) and an uncontrollable factor (Y). In both cases, the removal of X can result in a meaningful reduction in overall disease risk. It is hypothesized that even when the magnitude of overall risk reduction brought by the removal of X is the same in the two cases, people would have a lower motivation to remove X in the latter case.

The investigators also examine how the presence of an uncontrollable risk factor interacts with the respondents' regret anticipation to influence their decision to remove X. In the context of the current research, regret anticipation could take one of the following forms: (a) feel regretful if one decides not to remove X and later develops the disease (b) feel regretful if one decides to remove X but still develops the disease. The investigators expect (a) to moderate the effect of uncontrollable risk factor on motivation to remove X.

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

200

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Hong Kong, Hong Kong
        • Reclutamiento
        • Chinese University of Hong Kong
        • Contacto:
          • Wing Man Yeung, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • students enrolled in marketing courses at the Chinese University of Hong Kong

Exclusion Criteria:

  • None

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación factorial
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: Uncontrollable factor ABSENT; NO anticipated regret induced

The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5 (Hong Kong dollars). Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.

There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. A cause, X, is identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points.

Experimental: Uncontrollable factor ABSENT; anticipated regret induced
Same description as in the "uncontrollable factor absent, no anticipated regret induced" arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease.
mayor nivel de elaboración sobre el arrepentimiento potencial
Experimental: Uncontrollable factor PRESENT; NO anticipated regret induced

The experiment comprises 10 rounds of decision tasks. For each round, the participant begins with having 130 points, each worth $0.5. Different numbers of points are deducted depending on the outcome in each round. After the 10 rounds, the computer randomly selects 1 of the rounds and the points from this round is paid in cash.

There is a chance for the participant to develop a disease. Without prevention, the chance of getting the disease is 60%. Two causes, X and Y, are identified for the disease. The participant has to decide whether or not to remove X. Removal of X reduces disease chance; the reduced chance varies between 10% and 50% across the 10 rounds and the exact level is communicated at the beginning of each round. The removal of X costs 30 points. Whether s/he ends up developing the disease or not is determined by a computerized lottery based on these chances. If s/he develops the disease, s/he will lose 100 points.

the presence of an uncontrollable / unremovable risk factor for a disease
Experimental: Uncontrollable factor PRESENT; anticipated regret induced
Same as the "uncontrollable factor present, no anticipated regret induced" arm, except that the participants are induced to think to what extent they will feel regretful: a) if s/he decides not to remove X but ends up developing the disease and b) if s/he decides to remove X but still gets the disease.
mayor nivel de elaboración sobre el arrepentimiento potencial
the presence of an uncontrollable / unremovable risk factor for a disease

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Decisión de eliminar X
Periodo de tiempo: Día 1: Al responder al cuestionario
La decisión de eliminar X (sí vs. no)
Día 1: Al responder al cuestionario

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Anticipated regret
Periodo de tiempo: Day 1: When responding to the questionnaire.
The exact question is: Some people may engage in the following thoughts when they make their decisions: "I may regret if I do not remove X and end up getting the disease" OR "I may regret if I remove X but still get the disease." To what extent have you engaged in any of these thoughts? (Measurement scale: 1 = not at all; 7 = a lot)
Day 1: When responding to the questionnaire.
Judgment of whether the removal of X is an opportunity to improve earnings
Periodo de tiempo: Day 1: When responding to the questionnaire.
The exact question is: Do you think the decision to remove X is an opportunity for you to improve your final earnings? (Measurement scale: 1 = not a good opportunity at all; 7 = a very good opportunity")
Day 1: When responding to the questionnaire.
Sense of control over the final outcome
Periodo de tiempo: Day 1: When responding to the questionnaire.
The exact question is: Do you think you have control over the outcome through your decision of whether or not to remove X? (Measurement scale: 1 = I have very little control… 7 = I have a lot of control)
Day 1: When responding to the questionnaire.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Investigador principal: Wing Man Yeung, PhD, Chinese University of Hong Kong

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

4 de abril de 2019

Finalización primaria (Anticipado)

1 de julio de 2019

Finalización del estudio (Anticipado)

1 de julio de 2019

Fechas de registro del estudio

Enviado por primera vez

2 de abril de 2019

Primero enviado que cumplió con los criterios de control de calidad

5 de abril de 2019

Publicado por primera vez (Actual)

9 de abril de 2019

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de abril de 2019

Última actualización enviada que cumplió con los criterios de control de calidad

5 de abril de 2019

Última verificación

1 de abril de 2019

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 14507018

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Data will be uploaded to file sharing sites for sharing. Any identifying information will be removed before data sharing.

Marco de tiempo para compartir IPD

Data will become available after manuscript is published, for 5 years starting from publication date.

Criterios de acceso compartido de IPD

Data will only be made available for research purpose.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir